Abstract
Survival outcomes for metastatic melanoma have drastically improved with the advent of immunotherapy. Access to ongoing immunotherapy clinical trials has become increasingly important to patients with advanced disease. We sought to quantify geographic disparities in access to these trials by U.S. division, region, urban/rural status, and median income. We searched ClinicalTrials.gov for interventional immunotherapy trials for metastatic melanoma from 2015 to 2021 and identified U.S. zip codes for each participating trial site. ArcGIS was used to calculate the one-way driving time from each zip code to the nearest treatment center. Melanoma burden in each zip code outside a 60 min driving radius was calculated by multiplying population by the corresponding state’s cancer-specific mortality rate. χ2 tests were used to test for significance between census regions, divisions, and urban vs. rural zip codes, while logistic regression was used to quantify risk of poor access with median income. Across 148 trials, 4844 treatment centers were located in 1102 unique zip codes. 9010 zip codes were located greater than one-hour driving time from the nearest clinical trial. Southern regions were most likely to have poor access of all regions (p < 0.001), and rural status also significantly correlated with poor access (p < 0.001). For every $10,000 increase in median income, the likelihood of a zip code being within 60 min from a trial increased by 1.315. While immunotherapy continue to improve survival outcomes for metastatic melanoma, geographic access to clinical trials investigating these therapies remains a challenge for a significant proportion of the U.S. population.
This is a preview of subscription content, log in via an institution to check access.
References
Aneja S, Aneja S, Bordeaux JS (2012) Association of increased dermatologist density with lower melanoma mortality. Arch Dermatol 148:174–178
Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J (2015) Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med 175:293–295
Hopkins ZH, Moreno C, Carlisle R, Secrest AM (2019) Melanoma prognosis in the United States: identifying barriers for improved care. J Am Acad Dermatol 80:1256–1262
Hsia R, Shen YC (2011) Possible geographical barriers to trauma center access for vulnerable patients in the United States: an analysis of urban and rural communities. Arch Surg 146:46–52
Jia JL, Turner BE, Azad AD, Chelliah MP, Weeks BT, Rasmussen HK, Zhu GA, Lewis MA (2021) Characteristics of dermatology clinical trials 2007–2018: insights from a systematic analysis of ClinicalTrials.gov. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2021.02.078
Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. J Investig Dermatol 129:1666–1674
McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40:1056–1064
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trialsrace-, sex-, and age-based disparities. JAMA 291:2720–2726
Malleshappa SKS, Smith G, Patel S, Mehta T, Appleman L, Huntington SF et al (2021) Overall survival based on oncologist density in the United States: A retrospective cohort study. PLoS One 16(5):e0250894. https://doi.org/10.1371/journal.pone.0250894
Sitenga JL, Aird G, Ahmed A, Walters R, Silberstein PT (2018) Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis. Int J Dermatol 57:1149–1156
Soares RR, Parikh D, Shields CN, Peck T, Gopal A, Sharpe J, Yonekawa Y (2021) Geographic access disparities to clinical trials in diabetic eye disease in the United States. Ophthalmol Retina 5:879–887
Soldozy S, Mulligan KM, Zheng DX, Levoska MA, Cullison CR, Elarjani T, Eichberg DG, Ampie LE, Shah AH, Yağmurlu K, Shaffrey ME, Scott JF, Komotar RJ (2021) Oncolytic virotherapy for melanoma brain metastases, a potential new treatment paradigm? Brain Sci 11:1260
U.S. Census Bureau (2020) Income in the past 12 months. Available at https://data.census.gov/cedsci/. Accessed 2 June 2022
U.S. Census Bureau (2010). Census regions and divisions of the United States. Available at: https://www.census.gov/geographies/reference-maps/2010/geo/2010-census-regions-and-divisions-of-the-unitedstates.html. Accessed 2 June 2022
USDA ERS - Rural-Urban Commuting Area Codes. Available at: https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx. Accessed June 2
Acknowledgements
The authors acknowledge R. Benjamin Gorham, PhD of the Freedman Center for Digital Scholarship at Case Western Reserve University in Cleveland, Ohio for assistance with ArcGIS Pro software.
Funding
The authors report no funding sources relevant to this work.
Author information
Authors and Affiliations
Contributions
Conceptualization: KMM, DXZ and JFS; data collection: KMM; graphics: KMM; statistical analysis: KMM, JRX, CRC, TBC; writing (original draft): KMM; writing (review and editing): DXZ, JX, CRC, TBC, MGB, JFS.
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest relevant to this work.
Informed consent
The Case Western Reserve University Institutional Review Board determined this study to be exempt from review and waived the requirement for informed consent owing to the use of deidentified data.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mulligan, K.M., Zheng, D.X., Xu, J.R. et al. Geographic disparities in access to immunotherapy clinical trials for metastatic melanoma. Arch Dermatol Res 315, 1033–1036 (2023). https://doi.org/10.1007/s00403-022-02433-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-022-02433-0